RxDoctor Payments Data

Carrie Totta, MD

Cardiovascular Disease · Lenexa, KSNPI 1508870593

Payments from drug & device makers

$2,506in general payments, 2019–2025

Across 140 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$316
  • Pfizer$307
  • Novartis$307
  • Boston Scientific$268
  • Merck$225
  • Johnson & Johnson$160
  • plus $923 from 18 others

What the payments were for

  • Food & beverage$2,45498%
  • Education$522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,506 in reported general payments places this provider in the 45th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$113,544
Medicare patients
772
Services billed
1,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$335,661
XareltoRivaroxaban119$113,104
JardianceEmpagliflozin93$75,828
Repatha SureclickEvolocumab38$44,275
MultaqDronedarone Hcl16$20,787
EntrestoSacubitril/Valsartan16$18,045
Metoprolol Succinate347$3,783
Atorvastatin Calcium430$3,597
Ezetimibe154$2,349
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,248
Rosuvastatin Calcium155$1,935
Losartan Potassium243$1,785
Potassium Chloride94$1,656
Carvedilol167$1,583
Torsemide56$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$307$335,661366 claims
Johnson & JohnsonXarelto$160$113,104119 claims
Boehringer IngelheimJardiance$316$75,82893 claims
Sanofi-aventis U.S. LLCMultaq$125$20,78716 claims
NovartisEntresto$307$18,04516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →